EYPT EyePoint Pharmaceuticals
- 11.700
- -0.360-2.99%
- 11.380
- -0.320-2.74%
EyePoint Pharmaceuticals News
Scotiabank Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Maintains Target Price $18
EyePoint Pharmaceuticals Is Maintained at Buy by Chardan Capital
EyePoint Pharmaceuticals Analyst Ratings
Capital One Financial Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Maintains Target Price $35
JonesTrading Initiates EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Announces Target Price $45
Baird Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Maintains Target Price $38
Analyst Ratings For EyePoint Pharmaceuticals
H.C. Wainwright Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Maintains Target Price $30
Positive Outlook for EyePoint Pharmaceuticals: Phase 3 LUGANO Trial for DURAVYU Boosts Buy Rating
Capital One Financial Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Maintains Target Price $35
Scotiabank Initiates Coverage On EyePoint Pharmaceuticals With Sector Outperform Rating, Announces Price Target of $18
Mizuho Securities Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating
EyePoint Pharmaceuticals (EYPT) Receives a Buy From Mizuho Securities
Capital One Financial Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Maintains Target Price $35
EyePoint Pharmaceuticals Price Target Announced at $15.00/Share by Jefferies
Jefferies Initiates EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Announces Target Price $15
Outperform Rating Reaffirmed for EyePoint Pharmaceuticals Amidst Promising Duravyu Developments
EyePoint Pharmaceuticals Analyst Ratings
JP Morgan Maintains Overweight on EyePoint Pharmaceuticals, Lowers Price Target to $29
J.P. Morgan Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Cuts Target Price to $29
Analysis
Price Target
No Data
No Data